Table 5. Treatment-emergent adverse events in study subjects (N=23).
| Preferred term | N (%) | Grade 3 and 4, n (%) |
|---|---|---|
| Thrombocytopenia | 15 (65) | 9 (39) |
| Neutropenia | 14 (61) | 11 (48) |
| Anemia | 11 (48) | 5 (22) |
| Fatigue | 12 (52) | 4 (17) |
| Diarrhea | 9 (39) | 1 (4) |
| Leukopenia | 9 (39) | 4 (17) |
| Nausea | 9 (39) | 0 (0) |
| Hypomagnesemia | 9 (39) | 0 (0) |
| Vomiting | 7 (30) | 0 (0) |
| Hyperglycemia | 7 (30) | 2 (9) |
| Hyponatremia | 6 (26) | 3 (4) |
| Hypokalemia | 5 (21) | 3 (4) |
| Decreased appetite | 5 (21) | 0 (0) |
| Dehydration | 5 (21) | 2 (9) |
| Dizziness | 4 (17) | 0 (0) |
| Peripheral sensory neuropathy | 4 (17) | 0 (0) |
| Dysgeusia | 3 (13) | 0 (0) |
| Hypocalcemia | 3 (13) | 1 (4) |
| QT prolongation | 3 (13) | 0 (0) |
| Edema peripheral | 3 (13) | 0 (0) |
| Urinary tract infection | 3 (13) | 0 (0) |
| Muscular weakness | 3 (13) | 0 (0) |
| Dysphagia | 3 (13) | 0 (0) |
| Hematuria | 3 (13) | 0 (0) |
| Respiratory failure | 3 (13) | 0 (0) |
| Cough | 5 (21) | 0 (0) |
| Dyspnea | 5 (21) | 1 (4) |